Skip to Content
MilliporeSigma
  • Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.

Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.

Journal of hepatology (2014-07-08)
Prue M Pereira-Fantini, Susan Lapthorne, Susan A Joyce, Nicole L Dellios, Guineva Wilson, Fiona Fouhy, Sarah L Thomas, Michelle Scurr, Colin Hill, Cormac G M Gahan, Paul D Cotter, Peter J Fuller, Winita Hardikar, Julie E Bines
ABSTRACT

Despite the mortality associated with liver disease observed in patients with short bowel syndrome (SBS), mechanisms underlying the development of SBS-associated liver disease (SBS-ALD) are poorly understood. This study examines the impact of bacterially-mediated bile acid (BA) dysmetabolism on farnesoid X receptor (FXR) signalling pathways and clinical outcome in a piglet model of SBS-ALD. 4-week old piglets underwent 75% small bowel resection (SBR) or sham operation. Liver histology and hepatic inflammatory gene expression were examined. Abundance of BA biotransforming bacteria was determined and metabolomic studies detailed the alterations in BA composition of stool, portal serum and bile samples. Gene expression of intestinal and hepatic FXR target genes and small heterodimer partner (SHP) transrepression targets were assessed. Histological evidence of SBS-ALD included liver bile duct proliferation, hepatocyte ballooning and fibrosis. Inflammatory gene expression was increased. Microbiota changes included a 10-fold decrease in Clostridium and a two-fold decrease in Bacteroides in SBS-ALD piglets. BA composition was altered and reflected a primary BA dominant composition. Intestinal and hepatic regulation of BA synthesis was characterised by a blunted intestinal FXR activation response and a failure of SHP to repress key hepatic targets. We propose a pathological scenario in which microbial dysbiosis following SBR results in significant BA dysmetabolism and consequent outcomes including steatorrhoea, persistent diarrhoea and liver damage. Furthermore alterations in BA composition may have contributed to the observed disturbance in FXR-mediated signalling pathways. These findings provide an insight into the complex mechanisms mediating the development of liver disease in patients with SBS.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-NR0B2 (ab1) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Chenodeoxycholic acid
Chenodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Cholic acid-2,2,4,4-d4, 98 atom % D, 98% (CP)